TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 14706580
Drug: Cimetidine hydrochloride
Normalized name: Cimetidine Hydrochloride
DrugBank: Cimetidine (DB00501)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cimetidine hydrochloride 1,200 mg daily (H(2)-blocker)
Study: 14706580
Drug: Ranitidine hydrochloride
Normalized name: Ranitidine Hydrochloride
DrugBank: Ranitidine (DB00863)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ranitidine hydrochloride 200 mg daily (H(2)-blocker)
Study: 14706580
Drug: Omeprazole 40
Normalized name: omeprazole 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 40 mg twice daily for 5 days
Study: 14706580
Drug: Neither H(2)-blocker
Normalized name: 2,2',3,3',4,4',5,5',6-nonachlorodiphenyl either
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neither H(2)-blocker nor omeprazole
Study: 3546716
Drug: Metronidazole (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metronidazole (1.5 g daily for 10 days)
Study: 3546716
Drug: Tinidazole (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tinidazole (1.5 g daily for 10 days)
Study: 3546716
Drug: Ornidazole (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ornidazole (1 g daily for 10 days)
Study: 3546716
Drug: Metronidazole (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metronidazole (0.5 g daily for 10 days)
Study: 3546716
Drug: Tinidazole (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tinidazole (single 2 g dose)
Study: 3546716
Drug: Ornidazole (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ornidazole (single 1 g dose)
Study: 23521140
Drug: Articaine 40
Normalized name: articaine 40 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Articaine 40 mg (20 mg/ml)
Study: 23842536
Drug: Oral ibuprofen
Normalized name: ibuprofen Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral ibuprofen (10 mg/kg)
Study: 17119689
Drug: Oral dipyrone
Normalized name: dipyrone
DrugBank: Metamizole (DB04817)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral dipyrone (15 mg/kg)
Study: 17119689
Drug: Intramuscular dipyrone
Normalized name: dipyrone
DrugBank: Metamizole (DB04817)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular dipyrone (15 mg/kg)
Study: 17119689
Drug: All groups
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All groups (oral ibuprofen, oral dipyrone, intramuscular dipyrone)
Study: 17119689
Drug: Oral dipyrone
Normalized name: dipyrone
DrugBank: Metamizole (DB04817)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral dipyrone
Study: 11026949
Drug: New forms
Approvals — FDA: no, EMA: no, PMDA: no
Description: New forms of psychological treatment for women newly diagnosed with early-stage breast cancer
Study: 11026949
Drug: New forms
Approvals — FDA: no, EMA: no, PMDA: no
Description: New forms of psychological treatment for families at risk of maladaptive bereavement
Study: 8792361
Drug: Aspirin (650
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (650 mg, 1 capsule/day for 14 days)
Study: 1284159
Drug: IS‐5‐MN 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: IS‐5‐MN 20 mg three times daily
Study: 1284159
Drug: Gallopamil 50
Normalized name: gallopamil 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gallopamil 50 mg three times daily
Study: 1284159
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of IS‐5‐MN and gallopamil (same dosages as above)
Study: 3969934
Drug: Weight lifting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weight lifting exercise with RDA protein intake (0.8 g/(kg BW X d))
Study: 30267294
Drug: Eluxadoline (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eluxadoline (75 mg or 100 mg)
Study: 24652494
Drug: A/California/7/2009(H1N1)-AS03 vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: A/California/7/2009(H1N1)-AS03 vaccine (Ad2 group)
Study: 24652494
Drug: Nonadjuvanted A/California/7/2009(H1N1)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonadjuvanted A/California/7/2009(H1N1) vaccine (NAd2 group)
Study: 24652494
Drug: A/California/7/2009(H1N1)-AS03 vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: A/California/7/2009(H1N1)-AS03 vaccine with saline placebo (control group)
Study: 12722044
Drug: Fluvastatin, 40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluvastatin, 40 mg/d (n = 13)
Study: 10831023
Drug: Donepezil HCl
Normalized name: donepezil HCl
DrugBank: Donepezil (DB00843)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Donepezil HCl 5 mg for 4 weeks, followed by 10 mg for 8 weeks
Study: 21555774
Drug: Self-administered teriparatide
Normalized name: Teriparatide
DrugBank: Teriparatide (DB06285)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Self-administered teriparatide
Study: 15001624
Drug: Testosterone (Te)
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testosterone (Te) 200 mg
Study: 7961108
Drug: Paclitaxel 180
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel 180 mg/m2
Study: 7961108
Drug: Paclitaxel 75-180
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel 75-180 mg/m2
Study: 7961108
Drug: Paclitaxel (various
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paclitaxel (various doses)
Study: 27059990
Drug: Continuous-flow cryocompression
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous-flow cryocompression therapy
Study: 18070947
Drug: Cell infusion
Normalized name: irrigation set MISCELL INFUSION SETS-PARAPHERNALIA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cell infusion with PBSCs mobilised by G-CSF
Study: 18070947
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no cell infusion)
Study: 14656453
Drug: Oral yohimbine
Normalized name: YOHIMBINE
DrugBank: Yohimbine (DB01392)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral yohimbine (20 mg)
Study: 14656453
Drug: Oral clonidine
Normalized name: Clonidine
DrugBank: Clonidine (DB00575)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral clonidine (150 mg)
Study: 11092167
Drug: Patient medication
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient medication counseling by a clinical pharmacist prior to discharge
Study: 1489941
Drug: Lithium citrate
Normalized name: Lithium Citrate
DrugBank: Lithium succinate (DB14508)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lithium citrate syrup
Study: 1489941
Drug: Lithium citrate
Normalized name: Lithium Citrate
DrugBank: Lithium succinate (DB14508)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lithium citrate syrup and Lithium carbonate tablets
Study: 29249880
Drug: Implant-retained mandibular
Normalized name: betaine
DrugBank: Betaine (DB06756)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Implant-retained mandibular overdenture
Study: 25498245
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil (FO, 1.2 g/d n‐3 LCPUFA)
Study: 19004197
Drug: Acupuncture plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture plus acupoint-injection
Study: 19004197
Drug: Oral administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of carbamazepine (Control)
Study: 12533551
Drug: Noncontact normothermic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Noncontact normothermic wound therapy
Study: 8592060
Drug: L-NAME (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-NAME (25 nmol)
Study: 8592060
Drug: L-NAME and
Normalized name: L-NAME
DrugBank: N-omega-nitro-L-arginine methyl ester (DB12750)
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-NAME and L-NMMA
Study: 8592060
Drug: L-NAME (12.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-NAME (12.5 or 25 pmol)
Study: 20565458
Drug: Rupatadine 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rupatadine 10 mg + Lorazepam 2 mg
Study: 15827094
Drug: Testosterone enanthate
Normalized name: Testosterone Enanthate
DrugBank: Testosterone enanthate (DB13944)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Testosterone enanthate (all doses)
Study: 12072596
Drug: Interferon alpha‐2b
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon alpha‐2b (3 MU three times weekly) for 52 weeks in combination with ribavirin
Study: 12072596
Drug: Interferon alpha‐2b
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon alpha‐2b (3 MU three times weekly) for 52 weeks without ribavirin (placebo)
Study: 3622594
Drug: Diltiazem 60
Normalized name: DILTIAZEM 60MG 12HR CAP,SA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diltiazem 60 mg thrice daily
Study: 20601163
Drug: Feedback intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Feedback intervention - patients complete monthly symptom surveys, and severity of symptoms is mailed to the renal provider with treatment options.
Study: 20601163
Drug: Management intervention
Approvals — FDA: no, EMA: no, PMDA: no
Description: Management intervention - patients complete monthly symptom surveys and are evaluated by a symptom management nurse who provides recommendations for treatment.
Study: 15861085
Drug: Tumescent lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tumescent lidocaine injection into the neck (lidocaine 0.1%, NaHCO3 12.5 mEq/L, epinephrine 1:1,000,000, 7 mg/kg)
Study: 15861085
Drug: Tumescent lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tumescent lidocaine injection into the thighs (lidocaine 0.1%, NaHCO3 12.5 mEq/L, epinephrine 1:1,000,000, 7 mg/kg)
Study: 15861085
Drug: Tumescent lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tumescent lidocaine injection into the neck
Study: 15861085
Drug: Tumescent lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tumescent lidocaine injection into the thighs
Study: 10378864
Drug: IFNbeta‐1a (Avonex)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IFNbeta‐1a (Avonex) treatment for 104 weeks
Study: 10378864
Drug: IFNbeta‐1a (Avonex)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IFNbeta‐1a (Avonex) treatment
Study: 1658942
Drug: Logiparin 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Logiparin 50 mg/kg body weight once daily for 7 days, starting 2 hours preoperatively.
Study: 1658942
Drug: Placebo once
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo once daily for 7 days, starting 2 hours preoperatively.
Study: 30328725
Drug: Preservative-free tafluprost/timolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preservative-free tafluprost/timolol fixed combination (TTFC) administered in the evening (20:00) for 3 months
Study: 30328725
Drug: Preservative-free tafluprost/timolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preservative-free tafluprost/timolol fixed combination (TTFC) administered in the morning (08:00) for 3 months
Study: 30328725
Drug: Preserved latanoprost
Normalized name: Latanoprost
DrugBank: Latanoprost (DB00654)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Preserved latanoprost monotherapy
Study: 26383099
Drug: Insect therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insect therapy (5 crickets in a cage with sufficient fodder and a detailed instruction manual)
Study: 26383099
Drug: Insect therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insect therapy
Study: 24899596
Drug: Omega-3 PUFA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omega-3 PUFA supplementation (2710 mg EPA/day and 2040 mg DHA/day for one month)
Study: 22329674
Drug: pantoprazole 40
Normalized name: pantoprazole 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: pantoprazole 40 mg daily
Study: 20398020
Drug: Low-dose prednisone
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose prednisone comedication
Study: 20398020
Drug: Non-low-dose prednisone
Normalized name: Prednisone
DrugBank: Prednisone acetate (DB14646)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Non-low-dose prednisone (control group)
Study: 17993770
Drug: 5 h
Normalized name: B-75 High Potency
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 h i.v. infusion of active ghrelin
Study: 25778837
Drug: Parental trait
Normalized name: C.I. direct red 28 parent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parental trait anxiety pre- and post-treatment
Study: 11580151
Drug: Interferon continued
Normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon continued for 1 more year with gradual reduction of the dose
Study: 9578788
Drug: DTPw-HB vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: DTPw-HB vaccine booster dose at 18 months of age
Study: 3475196
Drug: Cefotiam in
Normalized name: cefotiam
DrugBank: Cefotiam (DB00229)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cefotiam in 2 doses of 2 g for 5 days
Study: 3475196
Drug: Cefotiam in
Normalized name: cefotiam
DrugBank: Cefotiam (DB00229)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cefotiam in 2 doses of 2 g only perioperatively
Study: 3475196
Drug: Ceftriaxone in
Normalized name: ceftriaxone Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftriaxone in a single dose of 2 g preoperatively
Study: 3475196
Drug: Low-dose prophylaxis
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose prophylaxis with 1 g ceftriaxone preoperatively
Study: 25848848
Drug: 550 mg
Normalized name: xylitol 550 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 550 mg NSAID + paracervical block (group 2)
Study: 25848848
Drug: 550 mg
Normalized name: xylitol 550 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 550 mg NSAID + paracervical analgesic cream (group 3)
Study: 25848848
Drug: 550 mg
Normalized name: xylitol 550 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 550 mg NSAID (group 1)
Study: 25848848
Drug: 550 mg
Normalized name: xylitol 550 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 550 mg NSAID + intrauterine analgesic instillation (group 4)
Study: 21282434
Drug: Conventional dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional dose of sulfadoxine-pyrimethamine (25/1.25 mg/kg of body weight)
Study: 21282434
Drug: Double dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Double dose of sulfadoxine-pyrimethamine (50/2.5 mg/kg of body weight)
Study: 2973693
Drug: Heat-treated recombinant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heat-treated recombinant DNA hepatitis B vaccine
Study: 2973693
Drug: Vaccine stored
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaccine stored at 4 degrees C
Study: 29675875
Drug: Supportive care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supportive care bundle (modulation of the infants' states, non‐nutritive sucking, facilitated tucking, and oral sucrose feeding)
Study: 20697092
Drug: Induction therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction therapy with single-agent rituximab followed by 4 cycles of maintenance therapy every 2 months (prolonged exposure)
Study: 20697092
Drug: Observation (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Observation (no further treatment after induction)
Study: 17015058
Drug: d-methamphetamine (0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: d-methamphetamine (0.25 mg/kg)
Study: 17015058
Drug: d-methamphetamine (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: d-methamphetamine (0.5 mg/kg)
Study: 17015058
Drug: racemic methamphetamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: racemic methamphetamine (0.5 mg/kg)
Study: 17015058
Drug: l-methamphetamine (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: l-methamphetamine (0.5 mg/kg)
Study: 17015058
Drug: l-methamphetamine (0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: l-methamphetamine (0.25 mg/kg)
Study: 14551525
Drug: Early statin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Early statin therapy started before discharge from hospital after an acute coronary syndrome
Study: 2491867
Drug: Intravenous recombinant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous recombinant tissue-type plasminogen activator (rt-PA) 100 mg
Study: 2491867
Drug: Intravenous streptokinase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous streptokinase 1.5 million units
Study: 184771
Drug: Topical corticosteroid
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical corticosteroid therapy (dexamethasone)
Study: 184771
Drug: Steroid-antibiotic preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Steroid-antibiotic preparation
Study: 184771
Drug: Corticosteroids (various
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticosteroids (various formulations)
Study: 21148045
Drug: Oral bosutinib
Normalized name: Bosutinib
DrugBank: Bosutinib (DB06616)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral bosutinib 100 mg alone
Study: 21148045
Drug: Oral bosutinib
Normalized name: Bosutinib
DrugBank: Bosutinib (DB06616)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral bosutinib 100 mg with ketoconazole 400 mg
Study: 17679042
Drug: Olmesartan medoxomil
Normalized name: Olmesartan Medoxomil
DrugBank: Olmesartan (DB00275)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Olmesartan medoxomil 40 mg (second study)
Study: 17679042
Drug: Valsartan 320
Normalized name: valsartan 320 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valsartan 320 mg (second study)
Study: 17679042
Drug: Irbesartan 300
Normalized name: irbesartan 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Irbesartan 300 mg (second study)
Study: 17679042
Drug: Valsartan 160
Normalized name: valsartan 160 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valsartan 160 mg (second study)
Study: 9884850
Drug: Single-dose spinal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose spinal anaesthesia (2.5 mL of bupivacaine 0.5% plain)
Study: 778366
Drug: Combined ampicillin
Normalized name: Ampicillin
DrugBank: Ampicillin (DB00415)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Combined ampicillin and gentamicin therapy with intrathecal administration of gentamicin
Study: 778366
Drug: Combined ampicillin
Normalized name: Ampicillin
DrugBank: Ampicillin (DB00415)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Combined ampicillin and gentamicin therapy without intrathecal administration of gentamicin
Study: 30636504
Drug: Methylnaltrexone (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylnaltrexone (8 or 12 mg according to weight)
Study: 26000677
Drug: Kiva VCF
Normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Kiva VCF Treatment System
Study: 7737135
Drug: Cyclophosphamide (CP)
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide (CP) treatment (50-200 mg/day)
Study: 7737135
Drug: Cyclophosphamide (CP)
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide (CP) treatment (high doses)
Study: 7737135
Drug: Patients without
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients without chemotherapy (n=5)
Study: 2407003
Drug: Prednisone (PRED)
Normalized name: Prednisone
DrugBank: Prednisone acetate (DB14646)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prednisone (PRED) therapy
Study: 2407003
Drug: No Prednisone
Normalized name: Prednisone
DrugBank: Prednisone acetate (DB14646)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: No Prednisone (NOPRED) therapy
Study: 34415
Drug: Chlorpheniramine (H1-receptor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorpheniramine (H1-receptor blocker)
Study: 34415
Drug: Cimetidine (H2-receptor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine (H2-receptor blocker)
Study: 34415
Drug: Chlorpheniramine and
Normalized name: Chlorpheniramine and epinephrine only product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorpheniramine and Cimetidine (both intravenous)
Study: 31298350
Drug: Recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Recombinant human basic fibroblast growth factor combined with compound polymyxin B ointment and local application of insulin
Study: 31298350
Drug: Compound polymyxin
Normalized name: BENZOIN COMPOUND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Compound polymyxin B ointment
Study: 25849681
Drug: Nitroglycerine infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitroglycerine infusion (NTG group)
Study: 17427617
Drug: Combination product
Normalized name: Drug-device combination product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination product of peppermint oil and caraway oil
Study: 17427617
Drug: Topical application
Normalized name: Talc Topical application Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical application of peppermint oil
Study: 17427617
Drug: Commonly recommended
Normalized name: Common carp
DrugBank: Common carp (DB10614)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Commonly recommended dosage of peppermint oil
Study: 11747323
Drug: Raloxifene 600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Raloxifene 600 mg daily
Study: 9010041
Drug: 4 mg
Normalized name: lutein 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg ibandronate
Study: 15251160
Drug: 6 mg
Normalized name: boron 6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 mg ibandronate
Study: 8343314
Drug: Previous aspirin
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Previous aspirin use
Study: 30894560
Drug: 40 g high
Normalized name: HIGH DENSITY POLYETHYLENE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 g high amylose RS2
Study: 19329015
Drug: Epidural infusion
Normalized name: epidural administration set EPIDURAL INFUSION SETS-PARAPHERNALIA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural infusion of 0.125% bupivacaine with 20 microg/kg/hr midazolam (Group BM)
Study: 19329015
Drug: Epidural infusion
Normalized name: epidural administration set EPIDURAL INFUSION SETS-PARAPHERNALIA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural infusion of 0.125% bupivacaine alone (Group B)
Study: 9689267
Drug: Dexamethasone 0.17
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone 0.17 mg/kg i.v.
Study: 9689267
Drug: Droperidol 0.02
Approvals — FDA: no, EMA: no, PMDA: no
Description: Droperidol 0.02 mg/kg i.v.
Study: 1198232
Drug: Prostaglandin E2
Normalized name: Prostaglandin E2
DrugBank: Dinoprostone (DB00917)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Prostaglandin E2 (PGE2) tablets